20.27
+35.77%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Delcath Systems
From its filings with the US Securities and Exchange Commission
Delcath Systems is based in Queensbury, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DCTH. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $85.2m and net income of $2.7m. At that date it held total assets of $123.6m and shareholders' equity of $111.2m. By business, HEPZATO KIT brought in 92.5% of revenue, followed by CHEMOSAT at 7.5%. By region, U.S. accounted for 92.5%, followed by Foreign at 7.5%.
We are an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver. Our lead product, the HEPZATOTM KIT (melphalan for Injection/Hepatic Delivery System), a drug/device combination product (“HEPZATO” or “HEPZATO KIT”), was approved by the US Food and Drug Administration (the “FDA”) on August 14, 2023, indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection, or radiation. The first commercial use of the HEPZATO for the treatment of metastatic hepatic dominant uveal melanoma (“mUM”) took place in January 2024.
In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted us six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Oct 2000
- Employees
- 156
- Website
- delcath.com ↗
- Head office
- 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. John SylvesterIndependent Non-Executive Chairman of the Board$229,169
- Mr. Gerard MichelChief Executive Officer, Director, since 2020$2.2m
- Ms. Sandra PennellChief Financial Officer
- Dr. Martha RookChief Operating Officer$933,097
- Mr. David HoffmanChief Compliance Officer, General Counsel, Corporate Secretary
- Mr. Kevin MuirGeneral Manager - Interventional Oncology$1.0m
- Dr. Vojislav VukovicChief Medical Officer$1.1m
- Dr. Gilad AharonIndependent Director$192,200
- Ms. Elizabeth CzerepakIndependent Director$205,673
- Dr. Bridget MartellIndependent Director$176,247
- Mr. Steven SalamonIndependent Director$204,130
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Delcath Systems Inc has developed a unique medical technology called the Delcath Hepatic Delivery System, which allows for targeted delivery of high-dose chemotherapy to the liver.
- The company's technology provides a more effective treatment option for patients with liver cancer and other liver-dominant metastases.
Weaknesses
- One of the main weaknesses of Delcath Systems Inc is its heavy reliance on a single product, the Delcath Hepatic Delivery System.
- The company may face challenges if competitors develop similar technologies or if the demand for their product decreases.
Opportunities
- The increasing incidence of liver cancer and the need for more effective treatment options provide Delcath Systems Inc with significant growth opportunities.
- The company can also explore partnerships with pharmaceutical companies to expand the use of their technology in other areas of oncology.
Threats
- Competition from established medical device companies and other emerging technologies is a major threat to Delcath Systems Inc.
- The strict regulatory environment and the need for extensive clinical trials could impact the company's ability to bring new products to market in a timely manner.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.